Oncolytic Effect of Zika Virus in Neuroendocrine Pancreatic Tumors: New Perspectives for Therapeutic Approaches.

Int J Mol Sci

Department of Research, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione), Via E. Tricomi 5, 90127 Palermo, Italy.

Published: December 2023

Pancreatic cancer (PCa) is the fifth leading cause of cancer mortality. Recently, our group and others have demonstrated the oncolytic activity of the Zika virus (ZIKV) against glioblastoma. The peculiar features of this virus offer the opportunity to use an agent already tested in vivo through natural transmission, with minimal effects on adults, to specifically target a tumor such as glioblastoma. This remarkable specificity prompted us to explore the potential use of ZIKV oncolytic action against other tumor types. In particular, we focused on the subgroup of pancreatic tumors with a neuroendocrine origin known as neuroendocrine tumors (NETs). We found that ZIKV exerts its oncolytic activity by specifically infecting NET cells, leading to growth inhibition and cell death. We also assessed whether the oncolytic action could be extended to pancreatic tumors different from NETs. However, as expected, the viral specificity is limited to NETs and is not applicable to adenocarcinoma tumors, indicating a narrow spectrum of action for this virus. These findings support the potential use of ZIKV in therapeutic approaches not only in glioblastoma, but also against other tumors, such as neuroendocrine pancreatic tumors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10743494PMC
http://dx.doi.org/10.3390/ijms242417271DOI Listing

Publication Analysis

Top Keywords

pancreatic tumors
16
zika virus
8
neuroendocrine pancreatic
8
therapeutic approaches
8
oncolytic activity
8
potential zikv
8
oncolytic action
8
tumors neuroendocrine
8
tumors nets
8
tumors
7

Similar Publications

KRAS is a proto-oncogene that is found to be mutated in 15% of all metastatic cancers with high prevalence in pancreatic, lung, and colorectal cancers. Additionally, patients harboring KRAS mutations respond poorly to standard cancer therapy. As a result, KRAS is seen as an attractive target for targeted anticancer therapy.

View Article and Find Full Text PDF

In order to make the drugs can cure the tumor precisely, this paper establishes the tumor immune dynamic model through the differential equation of tumor growth and analyzes the persistence of the tumor immune model. Research on dual anticancer drugs and commonly used coupling methods is carried out to complete the synthesis of polyethylene glycol dual anticancer drug couplers and the antitumor activity is analyzed to derive the degree of inhibition of polyethylene glycol dual anticancer drugs on tumor activity. From the four judging criteria, it was concluded that the polyethylene glycol bis-anti-cancer drug has a better curative effect on tumor cells.

View Article and Find Full Text PDF

Targeting KRAS: from metabolic regulation to cancer treatment.

Mol Cancer

January 2025

Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, China.

The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRAS-specific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance.

View Article and Find Full Text PDF

Impact of postoperative morbidity on the prognosis of patients with hepatocellular carcinoma after laparoscopic liver resection: a multicenter observational study.

Sci Rep

January 2025

Department of Comprehensive Surgery, Vascular Surgery, Nantong First People's Hospital, Affiliated Hospital 2 of Nantong University, 666 Shengli Road, Chongchuan District, Nantong City, 226014, Jiangsu Province, China.

The long-term impact of postoperative morbidity following laparoscopic liver resection for hepatocellular carcinoma is unclear. This study aimed to investigate whether the prognosis of hepatocellular carcinoma patients were affected by postoperative morbidity after laparoscopic liver resection. Hepatocellular carcinoma patients who underwent curative-intent laparoscopic liver resection were included.

View Article and Find Full Text PDF

Q&A with Lin Shen.

Med

January 2025

Professor Lin Shen, MD, graduated from Xuzhou Medical College in 1984 and Beijing Medical University in 1995. She trained at the US National Institutes of Health in 2000, focusing on therapies for gastrointestinal tumors. Currently, she is director of the Department of Gastrointestinal Oncology and Department of Early Drug Development Center, Peking University Cancer Hospital.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!